BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boyer O, Noël LH, Balzamo E, Guest G, Biebuyck N, Charbit M, Salomon R, Frémeaux-Bacchi V, Niaudet P. Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits. Am J Kidney Dis 2008;51:671-7. [PMID: 18371543 DOI: 10.1053/j.ajkd.2007.11.032] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Haerynck F, Stordeur P, Vandewalle J, Van Coster R, Bordon V, De Baets F, Schelstraete P, Javaux C, Bouvry M, Fremeaux-bacchi V, Dehoorne J. Complete Factor I Deficiency Due to Dysfunctional Factor I with Recurrent Aseptic Meningo-Encephalitis. J Clin Immunol 2013;33:1293-301. [DOI: 10.1007/s10875-013-9944-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
2 Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol. 2012;8:634-642. [PMID: 23026947 DOI: 10.1038/nrneph.2012.213] [Cited by in Crossref: 97] [Cited by in F6Publishing: 81] [Article Influence: 9.7] [Reference Citation Analysis]
3 Kumar A, Ramachandran R, Rawat A, Das R, Rayat CS, Kenwar DB, Sharma A, Gupta KL, Nada R. Poor allograft outcome in Indian patients with post-transplant C3 glomerulopathy. Clin Kidney J 2021;14:291-300. [PMID: 33564431 DOI: 10.1093/ckj/sfz135] [Reference Citation Analysis]
4 Green H, Harari E, Davidovits M, Blickstein D, Grossman A, Gafter U, Gafter-gvili A. Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab. Renal Failure 2014;36:1119-21. [DOI: 10.3109/0886022x.2014.917574] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
5 Ding Y, Zhao W, Zhang T, Qiang H, Lu J, Su X, Wen S, Xu F, Zhang M, Zhang H, Zeng C, Liu Z, Chen H. A haplotype in CFH family genes confers high risk of rare glomerular nephropathies. Sci Rep 2017;7:6004. [PMID: 28729648 DOI: 10.1038/s41598-017-05173-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
6 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
7 Nilsson SC, Sim RB, Lea SM, Fremeaux-bacchi V, Blom AM. Complement factor I in health and disease. Molecular Immunology 2011;48:1611-20. [DOI: 10.1016/j.molimm.2011.04.004] [Cited by in Crossref: 91] [Cited by in F6Publishing: 74] [Article Influence: 8.3] [Reference Citation Analysis]
8 Nester CM, Smith RJ. Treatment options for C3 glomerulopathy. Curr Opin Nephrol Hypertens. 2013;22:231-237. [PMID: 23318699 DOI: 10.1097/mnh.0b013e32835da24c] [Cited by in Crossref: 43] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
9 Abbas F, El Kossi M, Jin JK, Sharma A, Halawa A. De novo glomerular diseases after renal transplantation: How is it different from recurrent glomerular diseases? World J Transplant 2017; 7(6): 285-300 [PMID: 29312858 DOI: 10.5500/wjt.v7.i6.285] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
10 Vernon KA, Ruseva MM, Cook HT, Botto M, Malik TH, Pickering MC. Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy. J Am Soc Nephrol. 2016;27:1334-1342. [PMID: 26374608 DOI: 10.1681/asn.2015030295] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
11 Boon CJ, van de Kar NC, Klevering BJ, Keunen JE, Cremers FP, Klaver CC, Hoyng CB, Daha MR, den Hollander AI. The spectrum of phenotypes caused by variants in the CFH gene. Molecular Immunology 2009;46:1573-94. [DOI: 10.1016/j.molimm.2009.02.013] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 4.7] [Reference Citation Analysis]
12 Nilsson SC, Kalchishkova N, Trouw LA, Fremeaux-Bacchi V, Villoutreix BO, Blom AM. Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. Eur J Immunol 2010;40:172-85. [PMID: 19877009 DOI: 10.1002/eji.200939280] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
13 Huzmeli C, Candan F, Seker A, Yildiz E, Terzi H, Kayatas M. C3 mesangial proliferative glomerulonephritis initially presenting with atypical hemolytic uremic syndrome: a case report. J Med Case Rep 2016;10:206. [PMID: 27460033 DOI: 10.1186/s13256-016-0992-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
14 Garland DL, Pierce EA, Fernandez-Godino R. Complement C5 is not critical for the formation of sub-RPE deposits in Efemp1 mutant mice. Sci Rep 2021;11:10416. [PMID: 34001980 DOI: 10.1038/s41598-021-89978-8] [Reference Citation Analysis]
15 Regunathan-Shenk R, Avasare RS, Ahn W, Canetta PA, Cohen DJ, Appel GB, Bomback AS. Kidney Transplantation in C3 Glomerulopathy: A Case Series. Am J Kidney Dis 2019;73:316-23. [PMID: 30413277 DOI: 10.1053/j.ajkd.2018.09.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
16 Tamura T, Unagami K, Okumi M, Kakuta Y, Horita S, Ishida H, Koike J, Honda K, Tanabe K, Nitta K. A case of recurrent proliferative glomerulonephritis with monoclonal IgG deposits or de novo C3 glomerulonephritis after kidney transplantation. Nephrology (Carlton) 2018;23 Suppl 2:76-80. [PMID: 29968411 DOI: 10.1111/nep.13280] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 De Vriese AS, Sethi S, Van Praet J, Nath KA, Fervenza FC. Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach. J Am Soc Nephrol. 2015;26:2917-2929. [PMID: 26185203 DOI: 10.1681/asn.2015020184] [Cited by in Crossref: 53] [Cited by in F6Publishing: 27] [Article Influence: 7.6] [Reference Citation Analysis]
18 Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82:454-464. [PMID: 22456601 DOI: 10.1038/ki.2012.63] [Cited by in Crossref: 328] [Cited by in F6Publishing: 285] [Article Influence: 32.8] [Reference Citation Analysis]
19 Nahm JH, Song SH, Kim YS, Cheong HI, Lim BJ, Kim BS, Jeong HJ. De novo C3 glomerulonephritis in a renal allograft. Ultrastruct Pathol. 2016;40:112-115. [PMID: 26986539 DOI: 10.3109/01913123.2016.1154634] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
20 Zipfel PF, Smith RJ, Skerka C. Factor I and factor H deficiency in renal diseases: similar defects in the fluid phase have a different outcome at the surface of the glomerular basement membrane. Nephrol Dial Transplant 2009;24:385-7. [PMID: 19056782 DOI: 10.1093/ndt/gfn652] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
21 Wong EKS, Kavanagh D. Diseases of complement dysregulation-an overview. Semin Immunopathol 2018;40:49-64. [PMID: 29327071 DOI: 10.1007/s00281-017-0663-8] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
22 Kakita H, Miyake T, Komiya T, Tsukamoto T, Muso E. A case report of recurrent C3 glomerulonephritis 18 months after renal transplantation. Ren Replace Ther 2016;2. [DOI: 10.1186/s41100-016-0049-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26:41-57. [PMID: 20556434 DOI: 10.1007/s00467-010-1556-4] [Cited by in Crossref: 87] [Cited by in F6Publishing: 74] [Article Influence: 7.3] [Reference Citation Analysis]
24 Fakhouri F, de Jorge EG, Brune F, Azam P, Cook HT, Pickering MC. Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int 2010;78:279-86. [PMID: 20445496 DOI: 10.1038/ki.2010.132] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 5.4] [Reference Citation Analysis]
25 Smith-Jackson K, Yang Y, Denton H, Pappworth IY, Cooke K, Barlow PN, Atkinson JP, Liszewski MK, Pickering MC, Kavanagh D, Cook HT, Marchbank KJ. Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice. J Clin Invest 2019;129:1061-75. [PMID: 30714990 DOI: 10.1172/JCI99296] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
26 Savige J, Amos L, Ierino F, Mack HG, Symons RC, Hughes P, Nicholls K, Colville D. Retinal disease in the C3 glomerulopathies and the risk of impaired vision. Ophthalmic Genet 2016;37:369-76. [PMID: 26915021 DOI: 10.3109/13816810.2015.1101777] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
27 Bienaime F, Dragon-Durey MA, Regnier CH, Nilsson SC, Kwan WH, Blouin J, Jablonski M, Renault N, Rameix-Welti MA, Loirat C. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int. 2010;77:339-349. [PMID: 20016463 DOI: 10.1038/ki.2009.472] [Cited by in Crossref: 121] [Cited by in F6Publishing: 108] [Article Influence: 9.3] [Reference Citation Analysis]
28 Filippone EJ, Newman ED, Li L, Gulati R, Farber JL. Thrombotic Microangiopathy, an Unusual Form of Monoclonal Gammopathy of Renal Significance: Report of 3 Cases and Literature Review. Front Immunol 2021;12:780107. [PMID: 34858436 DOI: 10.3389/fimmu.2021.780107] [Reference Citation Analysis]
29 Lorcy N, Rioux-Leclercq N, Lombard ML, Le Pogamp P, Vigneau C. Three kidneys, two diseases, one antibody? Nephrol Dial Transplant. 2011;26:3811-3813. [PMID: 21813829 DOI: 10.1093/ndt/gfr436] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
30 Gnappi E, Allinovi M, Vaglio A, Bresin E, Sorosina A, Pilato FP, Allegri L, Manenti L. Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case. Pediatr Nephrol 2012;27:1995-9. [DOI: 10.1007/s00467-012-2210-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]